Abstract
Angiotensin converting enzyme – a new prognostic marker of recurrence in the treatment of prostate cancer
Highlights
Introduction to the clinical practice of new criteria for the diagnosis and monitoring of neoplastic processes in the prostate based on the identification of informative predictors and markers of prostate cancer (PC), especially its aggressive forms, is one of the priority directions of scientific research in oncological urology
For identification associated with PC progression indicators – potential markers clinically aggressive forms of PC was determined activity kininase II (angiotensin-converting enzyme (ACE), EC 3.4.15.1) in serum of blood with using as substrate N-(3-(2-furyl) acryloyl)-L-phenylalanyl-glycyl-glycine (FAPGG)
It has been shown that the development of PC recurrence is associated with an increase in ACE activity, and the ACE activity starts to grow sooner than noted the development of biochemical recurrence
Summary
Introduction to the clinical practice of new criteria for the diagnosis and monitoring of neoplastic processes in the prostate based on the identification of informative predictors and markers of prostate cancer (PC), especially its aggressive forms, is one of the priority directions of scientific research in oncological urology. For identification associated with PC progression indicators – potential markers clinically aggressive forms of PC was determined activity kininase II (angiotensin-converting enzyme (ACE), EC 3.4.15.1) in serum of blood with using as substrate N-(3-(2-furyl) acryloyl)-L-phenylalanyl-glycyl-glycine (FAPGG). ПСА синтезируется всеми эпителиальными клетками предстательной железы (нормальными, гиперпластическими или опухолевыми), что, несомненно, снижает его специфичность как биомаркера РПЖ. При локализованном РПЖ с низкой вероятностью поражения лимфатических узлов, высокой степенью дифференцировки опухоли и уровнем ПСА ≤ 20 нг / мл лучевую терапию проводили в режиме монотерапии. Согласно рекомендациям Американского общества терапевтической радиологии и онкологии (American Society for Therapeutic Radiology and Oncology) критерием биохимической прогрессии после наружной лучевой терапии являются 3 последовательных повышения уровня ПСА (ПСА ≥ 2 нг / мл относительно надира уровня ПСА), независимо от его значения [13, 14]. На основе ПСА-мониторинга ретроспективно стратифицировали группы пациентов: с развитием биохимического рецидива и клиническими признаками рецидива и с безрецидивным течением
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
